{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:59:27Z","timestamp":1783688367940,"version":"3.55.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Frailty, rather than age alone, is a key determinant of outcomes in older patients with multiple myeloma (MM), yet frailty assessments are often lacking in clinical trials. Consequently, data on the efficacy and tolerability of novel treatments in frail patients remain scarce. Moreover, there is substantial heterogeneity among frail patients, with some classified as frail solely due to age (&amp;gt;80 years) and others due to geriatric impairments and\/or comorbidities. To our knowledge, the HOVON 143 trial was the first trial that was specifically designed for frail patients with newly diagnosed MM (NDMM) using the International Myeloma Working Group Frailty Index (IMWG-FI). After a median follow-up of &amp;gt;5 years, we report the long-term progression-free survival (PFS) and overall survival (OS) outcomes, with detailed analyses of frail subgroups. Patients who were classified as frail according to the IMWG-FI were treated with 9 induction cycles of ixazomib, daratumumab, and low-dose dexamethasone, followed by maintenance therapy until progression for a maximum of 2 years. Median PFS was 13.8 months, and median OS was 34.0 months. However, frail subgroup analyses based on geriatric impairments and comorbidities besides age revealed pronounced heterogeneity in outcomes. Both early relapse\u2013related and nonrelapse-related mortality rates were higher in ultrafrail patients and patients who were frail due to impairments than in patients who were frail based on age alone. These findings highlight the need for a more precise frailty definition to identify patients at the highest risk of early mortality. This trial was registered at www.clinicaltrialsregister.eu as EudraCT #2016-002600-90.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017394","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:02:24Z","timestamp":1755892944000},"page":"5828-5836","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-9550","authenticated-orcid":false,"given":"Febe","family":"Smits","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"3Department of Hematology, Haga Hospital, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaz","family":"Groen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A. M.","family":"Stege","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"van Kampen","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, Zuyderland Hospital, Sittard, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"van der Spek","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Nijhof","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz M.","family":"Bilgin","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Adrz Hospital, Goes, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"Thielen","sequence":"additional","affiliation":[{"name":"10Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Ludwig","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Bernhoven Hospital, Uden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther G. M.","family":"de Waal","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8716-0856","authenticated-orcid":false,"given":"Yorick","family":"Sandberg","sequence":"additional","affiliation":[{"name":"13Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-867X","authenticated-orcid":false,"given":"Alain","family":"Kentos","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Centre Hospitalier Jolimont, Haine-Saint-Paul, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert-Jan","family":"Timmers","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine, Amstelland Hospital, Amstelveen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josien C.","family":"Regelink","sequence":"additional","affiliation":[{"name":"16Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Westerman","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"de Heer","sequence":"additional","affiliation":[{"name":"18Department of Internal Medicine, Flevoziekenhuis, Almere, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christiane","family":"Vekemans","sequence":"additional","affiliation":[{"name":"19Department of Hematology, St. Luc Hospital, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazik","family":"Durdu-Rayman","sequence":"additional","affiliation":[{"name":"20Department of Internal Medicine, Franciscus Hospital, Schiedam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-0856","authenticated-orcid":false,"given":"Nicole C. H. P.","family":"de Graauw","sequence":"additional","affiliation":[{"name":"21Department of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-0354","authenticated-orcid":false,"given":"Maarten R.","family":"Seefat","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula F.","family":"Ypma","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Haga Hospital, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2025112509114383200_bib1","unstructured":"Howlader\n              N\n            , KrapchoM, MillderD. SEER cancer statistics review, 1975-2018. Accessed 4 April 2025. https:\/\/seer.cancer.gov\/csr\/1975_2018\/index.html."},{"issue":"9","key":"2025112509114383200_bib2","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2025112509114383200_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2025112509114383200_bib4","first-page":"220","article-title":"The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study","volume":"1","author":"Szabo","year":"2019","journal-title":"Clin Hematol Int"},{"issue":"1","key":"2025112509114383200_bib5","first-page":"228","article-title":"Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study","volume":"110","author":"Visram","year":"2025","journal-title":"Haematologica"},{"issue":"13","key":"2025112509114383200_bib6","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2025112509114383200_bib7","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1002\/hem3.85","article-title":"Assessing frailty in myeloma: the pursuit of simplicity may sacrifice precision of predicting clinical outcomes","volume":"8","author":"Groen","year":"2024","journal-title":"HemaSphere"},{"issue":"8","key":"2025112509114383200_bib8","doi-asserted-by":"crossref","first-page":"102051","DOI":"10.1016\/j.jgo.2024.102051","article-title":"Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma","volume":"15","author":"Gahagan","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"2025112509114383200_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025112509114383200_bib10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41375-025-02552-3","article-title":"Outcomes of frailty subgroups of older adults (age \u2265 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis","volume":"39","author":"Mian","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"2025112509114383200_bib11","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1038\/s41375-021-01162-z","article-title":"Improving the identification of frail elderly newly diagnosed multiple myeloma patients","volume":"35","author":"Stege","year":"2021","journal-title":"Leukemia"},{"issue":"25","key":"2025112509114383200_bib12","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025112509114383200_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-021-00464-w","article-title":"Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age &gt;80 in the IMWG frailty score","volume":"11","author":"D\u2019Agostino","year":"2021","journal-title":"Blood Cancer J"},{"issue":"22","key":"2025112509114383200_bib14","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025112509114383200_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2024-209653","article-title":"IMWG frailty score-adjusted therapy delivery reduces the early mortality risk in newly diagnosed the multiple myeloma: results of the UK myeloma research alliance (UK-MRA) myeloma XIV fitness trial","volume":"144","author":"Cook","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025112509114383200_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025112509114383200_bib17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2024-203045","article-title":"The IFM2017-03 phase 3 trial: a dexamethasone sparing-regimen with daratumumab and lenalidomide for frail patients with newly-diagnosed multiple myeloma","volume":"144","author":"Manier","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025112509114383200_bib18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2025112509114383200_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2025112509114383200_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/cells10030665","article-title":"Pre-clinical evaluation of the proteasome inhibitor ixazomib against bortezomib-resistant leukemia cells and primary acute leukemia cells","volume":"10","author":"Roeten","year":"2021","journal-title":"Cells"},{"issue":"S1","key":"2025112509114383200_bib21","first-page":"e104","article-title":"Heterogeneity among frail myeloma patients, from \u201cfrail based on age\u201d to \u201cultra-frail\u201d, is associated with clinical outcome [abstract]","volume":"8","author":"Groen","year":"2024","journal-title":"HemaSphere"},{"issue":"2","key":"2025112509114383200_bib22","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"2025112509114383200_bib23","first-page":"490","article-title":"Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T cell therapy","volume":"30","author":"Johnson","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2025112509114383200_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"17","key":"2025112509114383200_bib25","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","article-title":"Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience","volume":"8","author":"Kalariya","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025112509114383200_bib26","first-page":"298","article-title":"Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"suppl 1","key":"2025112509114383200_bib27","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1182\/blood-2024-201824","article-title":"Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed\/refractory multiple myeloma","volume":"144","author":"Adegbite","year":"2024","journal-title":"Blood"},{"issue":"S3","key":"2025112509114383200_bib28","doi-asserted-by":"crossref","first-page":"e051743c","DOI":"10.1097\/01.HS9.0000970424.05174.3c","article-title":"Efficacy and safety of elranatamab by age and frailty in patients with relapsed\/refractory multiple myeloma (RRMM): a subgroup analysis from MAGNETISMM-3","volume":"7","author":"Leleu","year":"2023","journal-title":"HemaSphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5828\/2420426\/blooda_adv-2025-017394-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5828\/2420426\/blooda_adv-2025-017394-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:11:50Z","timestamp":1764079910000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5828\/546866\/Frail-subgroups-determine-heterogeneous-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":28,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017394","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,14]]}}}